search
Back to results

The Importance of Additional Protein to Benefit More From Training During and After Hospitalization (PEPOP)

Primary Purpose

Sarcopenia

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Protein
Placebo
Resistance training
Vitamin D
Sponsored by
Forskningsenheden
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Sarcopenia focused on measuring Sarcopenia, Muscular atrophy, Frailty, Acute illness, Ageing, Protein supplementation, Whey protein, Resistance training, Strength training

Eligibility Criteria

70 Years - undefined (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Men and women aged ≥ 70 years old
  • Able to speak and understand Danish
  • Expected length of stay > 3 days (evaluated by medical staff at department)
  • Ability to stand independently without walking aids
  • Admitted to the medical departments of Gentofte or Herlev Hospital or Rigshospitalet-Glostrup

Exclusion Criteria:

  • Active cancer
  • Renal insufficiency (eGFR < 30 mL/min/1.73m2)
  • Cognitive impairment (not able to comprehend the purpose of the study/give informed consent)
  • Terminal disease
  • Exclusively receiving enteral or parenteral nutrition
  • Milk/lactose allergy or intolerance
  • Planning to lose weight/go on a special diet
  • Planned transfer to other hospitals/departments
  • Pacemaker/other implanted electrical stimulants (due to Bio-Impedance Analysis (BIA) measurements)
  • Not being able to lie still in seven minutes (only an exclusion criteria in the sub-study)
  • Withdrawal criteria: Death during admission (does not apply to subsequent admissions)
  • Withdrawal criteria: Discharge/transfer from the medical department before the intervention has started

Sites / Locations

  • Copenhagen University Hospital Gentofte
  • Rigshospitalet-Glostrup
  • Copenhagen University Hospital Herlev

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Resistance training and protein

Resistance training and placebo

Arm Description

Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x 125 ml protein-enriched, milk-based supplements (whey protein), in the same period (additional ~25 g protein and 1953 kJ per day). Daily vitamin D supplements.

Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x125 ml iso-energetic placebo-supplements, in the same period. Daily vitamin D supplements.

Outcomes

Primary Outcome Measures

Change in 30-s chair stand performance
Number of stand-ups from a chair in 30 seconds (modified version, help from armrests are allowed).

Secondary Outcome Measures

Total lean body mass
Lean body mass (kg and percent) evaluated by bio-impedance analysis (portable, dual-frequency, 8-Point Tactile Electrode System).
Appendicular lean body mass
Appendicular lean body mass (kg and percent) evaluated by bio-impedance analysis (portable, dual-frequency, 8-Point Tactile Electrode System).
Trunk lean body mass
Trunk lean body mass (kg and percent) evaluated by bio-impedance analysis (portable, dual-frequency, 8-Point Tactile Electrode System).
Change in hand grip strength
Isometric hand grip strength (kg) (Saehan Medical digital dynamometer, 2012).
Change in 4 m gait speed
The time used for walking 4 m (m/s and s )
Change in Activities of daily living (ADL)
Use of Barthel-100
Change in mobility
Use of De Morton Mobility Index (DEMMI)
Change in cognitive functioning
Use of Mini Mental State Examination (MMSE)
Use of home care
Interview: (yes/no)
Residence
Interview: (own home, nursing home/assisted living facility, 24-hour rehabilitation facility)
Use of gait aid
Interview: yes/no/cannot walk and registration of specific gait help
Length of hospital stay (LOS)
The in-hospital intervention period (date of recruitment until date of discharge) (days)
Readmission to hospital
Frequency (number)
Length of total hospital stay for readmissions
Total length (days).
Mortality
Mortality (yes/no)
Change in health related Quality of life
Questionnaire: Euroqol EQ-5D-3L
Change in Body weight
Measured to the nearest 0.1 kg using a calibrated scale
Study population acceptance of product
Self-administered evaluation-questionnaire

Full Information

First Posted
March 9, 2016
Last Updated
August 20, 2018
Sponsor
Forskningsenheden
Collaborators
University of Copenhagen, The Danish Dairy Research Foundation, Denmark, Arla Foods, Glostrup University Hospital, Copenhagen, University Hospital, Gentofte, Copenhagen
search

1. Study Identification

Unique Protocol Identification Number
NCT02717819
Brief Title
The Importance of Additional Protein to Benefit More From Training During and After Hospitalization
Acronym
PEPOP
Official Title
A Protein-enriched, Milk-based Supplement to Counteract Sarcopenia in Acutely Ill Geriatric Patients Offered Resistance Exercise Training During and After Hospitalisation - a Double-blinded, Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
April 15, 2016 (Actual)
Primary Completion Date
December 20, 2017 (Actual)
Study Completion Date
June 20, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Forskningsenheden
Collaborators
University of Copenhagen, The Danish Dairy Research Foundation, Denmark, Arla Foods, Glostrup University Hospital, Copenhagen, University Hospital, Gentofte, Copenhagen

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to investigate if an increased protein intake, in the form of a protein-enriched, milk-based supplement, can enhance the beneficial effect of resistance training, offered during hospitalization and 12 weeks post discharge, in older patients. This will in part be evaluated from measures of muscle strength, muscle mass and physical functioning. Also, the study population's acceptance of the intervention product will be assessed along with measures related to 'cost-effectiveness'. A sub-study will be performed in a sub-group (n=30) to investigate if bio-impedance analysis (BIA) correlates with Dual-Energy X-ray absorptiometry (DXA) at single time points, and to see if it is possible to track changes in lean body mass. In addition, the reliability of the bio-impedance analyzer will be evaluated. Also, the prevalence and classification of sarcopenia will be assessed at baseline, and correlations to nutritional status will be investigated (n=120).
Detailed Description
Main study: The study design is a block randomised, double-blind, placebo-controlled, multicentre intervention study. A total of 120 hospitalized older adults, above 70 years, will be recruited consecutively from the medical departments of three Hospitals in the Capital Region of Denmark (n=40 each place). Participants will be randomized into two groups - one group receives protein-enriched, milk-based supplements and the other group receives iso-energetic placebo products. Both groups participate in the same standardized resistance training program, and will be blinded to the supplement content. One training session consists of three exercises of the lower extremities (3 sets of 10 repetitions, pursuing an intensity of 8-12 repetition maximum (RM)). While admitted, supervised resistance training is offered daily. After discharge, the participants are encouraged to perform the same program as self-training four times per week.To ensure progression (or regression if necessary) the participants receive follow-up home visits by a physiotherapist, and thus after discharge the participants are closely monitored. All participants, irrespective of allocation, will get a daily vitamin D supplement. The study duration for each participant starts while admitted to hospital and lasts until 12 weeks after discharge. Endpoint assessments will be performed at baseline (> 72-h after admission to hospital), after discharge (> 72-h) and 12 weeks (± 2 days) after discharge. A few endpoints will be collected during follow-up (6 months post intervention). Data will be collected by study investigators blinded to the allocation of the participants. Sub-study: 'Validation of a portable bio-impedance analyzer in a population of older adults ≥ 70 years for the assessment of muscle mass and changes in muscle mass over time' A sub-study will be performed to investigate if the portable InBody-230 BIA correlate with DXA at single time points in 30 hospitalized older people ≥ 70 years, and to see if it is possible to track changes in LBM during the 12-week intervention. Total LBM, total fat mass, and percent LBM will be measured and compared as well as appendicular and trunk LBM. In addition, the reliability of the portable bio-impedance analyzer will be evaluated by assessing the degree of agreement between two subsequent measurements. In continuation of recruitment to the primary study, a subset of participants (n=30) will be asked if they want to participate in this sub-study, irrespective of their allocation in the main study. The measurements are going to be performed twice, while hospitalized and 12 weeks after discharge (± 5 days). Sub-study: 'Prevalence of sarcopenia and investigation of the relationship between nutritional status and the EWGSOP conceptual stages for sarcopenia in hospitalized older patients > 70 years'. The prevalence and classification of sarcopenia among Danish hospitalized older patients ≥ 70 years old (n=120) will be evaluated, according to the EWGSOP definition (Hand-grip-strength, 4-m gait speed, Bio-Impedance analysis). Also, examination of the relationship between measurements of nutritional status and the EWGSOP stages for sarcopenia (i.e. no sarcopenia, pre-sarcopenia, sarcopenia and severe sarcopenia) will be assessed at baseline. Nutritional status will be assessed according to BMI (< 18.5, 18.5-20.5, 20.5-25, > 25), Mini Nutritional Assessment (MNA) (no MN, risk of MN, MN), Malnutrition Universal Screening Tool (MUST) (low risk of MN, medium risk of MN, high risk of MN), and NRS-2002 (no MN, mild MN, moderate MN, severe MN) Results will be communicated to the general population and published in peer-reviewed journals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcopenia
Keywords
Sarcopenia, Muscular atrophy, Frailty, Acute illness, Ageing, Protein supplementation, Whey protein, Resistance training, Strength training

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
165 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Resistance training and protein
Arm Type
Experimental
Arm Description
Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x 125 ml protein-enriched, milk-based supplements (whey protein), in the same period (additional ~25 g protein and 1953 kJ per day). Daily vitamin D supplements.
Arm Title
Resistance training and placebo
Arm Type
Placebo Comparator
Arm Description
Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x125 ml iso-energetic placebo-supplements, in the same period. Daily vitamin D supplements.
Intervention Type
Dietary Supplement
Intervention Name(s)
Protein
Other Intervention Name(s)
Protein-enriched, milk-based supplement (whey protein)
Intervention Description
Daily intake of supplement
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Other Intervention Name(s)
Iso-energetic placebo-supplement (no protein)
Intervention Description
Daily intake of supplement
Intervention Type
Other
Intervention Name(s)
Resistance training
Intervention Description
Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D
Intervention Description
Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
Primary Outcome Measure Information:
Title
Change in 30-s chair stand performance
Description
Number of stand-ups from a chair in 30 seconds (modified version, help from armrests are allowed).
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Secondary Outcome Measure Information:
Title
Total lean body mass
Description
Lean body mass (kg and percent) evaluated by bio-impedance analysis (portable, dual-frequency, 8-Point Tactile Electrode System).
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Appendicular lean body mass
Description
Appendicular lean body mass (kg and percent) evaluated by bio-impedance analysis (portable, dual-frequency, 8-Point Tactile Electrode System).
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Trunk lean body mass
Description
Trunk lean body mass (kg and percent) evaluated by bio-impedance analysis (portable, dual-frequency, 8-Point Tactile Electrode System).
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Change in hand grip strength
Description
Isometric hand grip strength (kg) (Saehan Medical digital dynamometer, 2012).
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Change in 4 m gait speed
Description
The time used for walking 4 m (m/s and s )
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Change in Activities of daily living (ADL)
Description
Use of Barthel-100
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Change in mobility
Description
Use of De Morton Mobility Index (DEMMI)
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Change in cognitive functioning
Description
Use of Mini Mental State Examination (MMSE)
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Use of home care
Description
Interview: (yes/no)
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Residence
Description
Interview: (own home, nursing home/assisted living facility, 24-hour rehabilitation facility)
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Use of gait aid
Description
Interview: yes/no/cannot walk and registration of specific gait help
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Length of hospital stay (LOS)
Description
The in-hospital intervention period (date of recruitment until date of discharge) (days)
Time Frame
Day of discharge (from hospital)
Title
Readmission to hospital
Description
Frequency (number)
Time Frame
From discharge until 12 weeks post discharge, and 6 months post discharge
Title
Length of total hospital stay for readmissions
Description
Total length (days).
Time Frame
From discharge until 12 weeks post discharge, and 6 months post discharge
Title
Mortality
Description
Mortality (yes/no)
Time Frame
From discharge until 12 weeks post discharge, and 6 months post discharge
Title
Change in health related Quality of life
Description
Questionnaire: Euroqol EQ-5D-3L
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Change in Body weight
Description
Measured to the nearest 0.1 kg using a calibrated scale
Time Frame
Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge
Title
Study population acceptance of product
Description
Self-administered evaluation-questionnaire
Time Frame
12 weeks post discharge
Other Pre-specified Outcome Measures:
Title
Lean body mass (sub group n=30)
Description
Lean body mass (total, appendicular, and trunk) evaluated by whole-body dual energy x-ray absorptiometry (DXA)-scanning.
Time Frame
Baseline (while admitted to hospital) and 12 weeks post discharge
Title
Fat mass (sub group n=30)
Description
Total mass. Evaluated by whole-body dual energy x-ray absorptiometry (DXA)-scanning and bio-impedance analysis (BIA).
Time Frame
Baseline (while admitted to hospital) and 12 weeks post discharge
Title
Reliability of bio-impedance analyzer in sub-group (n=30)
Description
Degree of agreement between two subsequent measurements.
Time Frame
Baseline (while admitted to hospital)
Title
Prevalence of sarcopenia
Description
According to the EWGSOP definition (yes/no).
Time Frame
Baseline (while admitted to hospital)
Title
Classification of sarcopenia
Description
According to the EWGSOP definition (pre-sarcopenia, sarcopenia, and severe sarcopenia).
Time Frame
Baseline (while admitted to hospital)
Title
Nutritional status - Body mass index (BMI)
Description
According to BMI (kg/m2) (< 18.5, 18.5-20.5, 20.5-25, > 25)
Time Frame
Baseline (while admitted to hospital)
Title
Nutritional status - Mini Nutritional Assessment (MNA)
Description
According to Mini Nutritional Assessment (MNA) (no malnutrition, risk of malnutrition, malnutrition).
Time Frame
Baseline (while admitted to hospital)
Title
Nutritional status - Malnutrition Universal Screening Tool (MUST)
Description
According to Malnutrition Universal Screening Tool (MUST) (low risk of MN, medium risk of MN, high risk of MN)
Time Frame
Baseline (while admitted to hospital)
Title
Nutritional status - Nutritional Risk Screening 2002 (NRS-2002)
Description
According to Nutritional Risk Screening 2002 (NRS-2002) (no MN, mild MN, moderate MN, severe MN).
Time Frame
Baseline (while admitted to hospital)
Title
Energy intake
Description
Daily registration schemes with pre-printed hospital foods and drinks (energy, kJ/kg).
Time Frame
4 days while admitted to hospital, or shorter if discharged
Title
Protein intake
Description
Daily registration schemes with pre-printed hospital foods and drinks (protein, g/kg).
Time Frame
4 days while admitted to hospital, or shorter if discharged
Title
Energy intake
Description
Dietary interviews x 4 (24-h recall interviews) (energy, kJ/kg).
Time Frame
From discharge until 12 weeks post discharge
Title
Protein intake
Description
Dietary interviews x 4 (24-h recall interviews) (protein, g/kg).
Time Frame
From discharge until 12 weeks post discharge
Title
Level of daily activity
Description
Activity interviews x 4 (recall interviews for the previous week)
Time Frame
From discharge until 12 weeks post discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men and women aged ≥ 70 years old Able to speak and understand Danish Expected length of stay > 3 days (evaluated by medical staff at department) Ability to stand independently without walking aids Admitted to the medical departments of Gentofte or Herlev Hospital or Rigshospitalet-Glostrup Exclusion Criteria: Active cancer Renal insufficiency (eGFR < 30 mL/min/1.73m2) Cognitive impairment (not able to comprehend the purpose of the study/give informed consent) Terminal disease Exclusively receiving enteral or parenteral nutrition Milk/lactose allergy or intolerance Planning to lose weight/go on a special diet Planned transfer to other hospitals/departments Pacemaker/other implanted electrical stimulants (due to Bio-Impedance Analysis (BIA) measurements) Not being able to lie still in seven minutes (only an exclusion criteria in the sub-study) Withdrawal criteria: Death during admission (does not apply to subsequent admissions) Withdrawal criteria: Discharge/transfer from the medical department before the intervention has started
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arne Astrup, DMSc
Organizational Affiliation
Copenhagen University Hospital at Herlev
Official's Role
Principal Investigator
Facility Information:
Facility Name
Copenhagen University Hospital Gentofte
City
Gentofte
ZIP/Postal Code
2820
Country
Denmark
Facility Name
Rigshospitalet-Glostrup
City
Glostrup
ZIP/Postal Code
2600
Country
Denmark
Facility Name
Copenhagen University Hospital Herlev
City
Herlev
ZIP/Postal Code
2730
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31337448
Citation
Gade J, Beck AM, Andersen HE, Christensen B, Ronholt F, Klausen TW, Vinther A, Astrup A. Protein supplementation combined with low-intensity resistance training in geriatric medical patients during and after hospitalisation: a randomised, double-blind, multicentre trial. Br J Nutr. 2019 Nov 14;122(9):1006-1020. doi: 10.1017/S0007114519001831.
Results Reference
derived
PubMed Identifier
29391380
Citation
Gade J, Beck AM, Bitz C, Christensen B, Klausen TW, Vinther A, Astrup A. Protein-enriched, milk-based supplement to counteract sarcopenia in acutely ill geriatric patients offered resistance exercise training during and after hospitalisation: study protocol for a randomised, double-blind, multicentre trial. BMJ Open. 2018 Feb 1;8(2):e019210. doi: 10.1136/bmjopen-2017-019210.
Results Reference
derived

Learn more about this trial

The Importance of Additional Protein to Benefit More From Training During and After Hospitalization

We'll reach out to this number within 24 hrs